



Tivozanib

Catalog No: tcsc0103

Available Sizes
Size: 5mg
Size: 10mg
Size: 50mg
Size: 100mg
Size: 200mg
Specifications
CAS No: 475108-18-0
Formula: $C_{22}^{H}_{19}^{CIN}_{4}^{O}_{5}$
Pathway: Protein Tyrosine Kinase/RTK
Target: VEGFR
Purity / Grade: >98%
Solubility: DMSO : 25 mg/mL (54.96 mM; Need ultrasonic)
Alternative Names: AV-951;KRN951





Observed Molecular Weight:

454.86

Product Description

Tivozanib (AV-951; KRN951) is a highly potent and selective **VEGFR 1/2/3** inhibitor with IC_{50} s of 0.21, 0.16, and 0.24 nM in cell assay, respectively.

IC50 & Target: IC50: 0.21 nM (VEGFR 1), 0.16 nM (VEGFR 2), 0.24 nM (VEGFR 3) $^{[1]}$

In Vitro: Tivozanib potently inhibits VEGF-induced VEGFR2 phosphorylation in endothelial cells (IC $_{50}$ =0.16 nM). It also inhibits ligand-induced phosphorylation of PDGFR β and c-Kit (IC $_{50}$ =1.72 and 1.63 nM, respectively). Tivozanib blocks VEGF-dependent, but not VEGF-independent, activation of mitogenactivated protein kinases and proliferation of endothelial cells. It inhibits VEGF-mediated migration of human umbilical vein endothelial cells^[1].

In Vivo: Following p.o. administration to athymic rats, Tivozanib decreases the microvessel density within tumor xenografts and attenuates VEGFR-2 phosphorylation levels in tumor endothelium. It also displays antitumor activity against a wide variety of human tumor xenografts, including lung, breast, colon, ovarian, pancreas, and prostate cancer^[1].

All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!